Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Read on to discover why many could benefit from investing in this terrific company. On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

New Xbox Series X games will start arriving thick and fast once over the next few months, with new exclusives launching on Microsoft's most powerful consoles. There's certainly a lot to look ...

CBSE Class 12 Maths MCQs: The CBSE Class 12 Maths Board Exam 2025, scheduled for March 08, 2025, requires dedicated practice, especially with Multiple-Choice Questions (MCQs), which are crucial ...

In this article, we are going to take a look at where United States Steel Corporation (NYSE:X) stands against other stocks that Jim Cramer commented discussed recently. On Thursday, Jim Cramer ...

Vertex Securities Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 35.08 Crore) operating in Financial Services sector. Vertex Securities Ltd. key ...

Vertex AI is a fully-managed, unified AI development platform for building and using generative AI. This repository is designed to help you get started with Vertex AI. Whether you're new to Vertex AI ...